Home Sectors Healthcare Latest Fundamentals: Anika Therapeutics (NASDAQ: ANIK)

Latest Fundamentals: Anika Therapeutics (NASDAQ: ANIK)


Anika Therapeutics is part of the healthcare sector and biotechnology industry. The company CEO is Joseph G. Darling. Anika Therapeutics Inc develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.

Previous Intraday Trading Performance:

The ANIK stock showed a previous change of -3.93% with an open at 30.57 and a close of 29.37. It reached an intraday high of 31.20 and a low of 29.05.

Business Wire:  Anika to Showcase Commercial and Pipeline Portfolio at 2019 AAOS Annual Meeting


The stock has a market cap of $417.4m with 14.2m shares outstanding, of which the float is 13.6m shares. Trading volume reached 315,034 shares compared to its average volume of 175,587 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Anika Therapeutics shares returned -5.68% and in the past 30 trading days it returned -22.55%. Over three months, it changed -6.20%. In one year it has changed -45.54% and within that year its 52-week high was 54.50 and its 52-week low was 28.54. ANIK stock is 2.91% above its 52 Week Low.

Our calculations show a 200 day moving average of 37.45 and a 50 day moving average of 35.29. Currently ANIK stock is trading -21.57% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

Business Wire:  Anika to Showcase Commercial and Pipeline Portfolio at 2019 AAOS Annual Meeting


The last annual fiscal EPS for the company was reported at 1.86 that ended on 31st of December 2018, which according to the previous close, that is a PE of 22.95. Based on 2 analyst estimates, the consensus EPS for the next quarter is 0.36. The TTM EPS is 1.86, which comes to a TTM PE of 15.79. Historically, the PE high was 38.00 and the PE low was 12.30. If the stock reached its PE low, that would represent a price of 22.88, which is a decrease of -22.10%.

The following are the last four quarter reported earnings per share:
12-31-2018:  0.54
09-30-2018:  0.53
06-30-2018:  0.68
03-31-2018:  0.11

Base on our calculations, the intrinsic value per share is 11.14, which means it may be overvalued by -163.56%

Indicators to Watch:

Based on the latest filings, there is 133.50% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.42

SeekingAlpha:  ANI Pharmaceuticals beats by $0.08, beats on revenue

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 7.26%, return on assets is 6.81%, profit margin is 18.44%, price-to-sales is 4.12 and price-to-book is 1.65.

Company Scores:

All scores are out of six:
 1  :Valuation Score
 0  :Past Performance Score
 6  :Financial Strength Score
 0  :Future Growth Score
 0  :Dividend Score
 1  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.